phrykt

Nurix Therapeutics, Inc. (NRIX): who owns it and who trades it

As of Nov 16, 2026, NRIX insiders reported 45 open-market sales worth $5.6M and no purchases in the last 12 months, with 81% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christine Ring (Chief Legal Officer), with $3.8M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Nurix Therapeutics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NRIX

212 funds and institutions reported NRIX shares worth $2.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 8.5%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.8.5%
Vestal Point Capital, LP7.8%
Deep Track Capital, LP7.5%
Rubric Capital Management LP7.0%
FMR LLC (Fidelity)5.3%
T. Rowe Price Associates5.2%
Morgan Stanley4.6%
State Street Corp4.5%
Baker Bros. Advisors LP4.5%
Vanguard Capital Management LLC4.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.8.77M8.45%$213M-2%
Vestal Point Capital, LP8.05M7.76%$195M+24%
Deep Track Capital, LP7.74M7.45%$188M+22%
Rubric Capital Management LP7.23M6.96%$175M+192%
FMR LLC (Fidelity)5.49M5.29%$133M-1%
T. Rowe Price Associates5.44M5.24%$132M+65%
Morgan Stanley4.76M4.59%$116M-3%
State Street Corp4.68M4.51%$113M-9%
Baker Bros. Advisors LP4.66M4.49%$113MNo change
Vanguard Capital Management LLC4.50M4.33%$109M+2%
Perceptive Advisors LLC4.32M4.16%$105M+16%
Redmile Group, LLC4.07M3.93%$98.8M-47%
General Atlantic, L.P.3.03M2.92%$73.6M-26%
Geode Capital Management, LLC2.54M2.44%$61.6M+1%
Pictet Asset Management Holding SA2.35M2.27%$57M-14%
ARK Investment Management LLC1.79M1.73%$43.5M+4%
Capital World Investors1.79M1.72%$43.4M+100%
California State Teachers Retirement System1.68M1.62%$69.3M+1598%
Trails Edge Capital Partners, LP1.57M1.52%$38.2M-10%
Vanguard Portfolio Management LLC1.48M1.43%$36M+35%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NRIX insiders reported $0 of open-market purchases and $5.6M of sales. 81% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$5.6M
45 trades, 4 people
Sales under a 10b5-1 plan
81%
Share of sale value
Latest trade
Nov 4, 2026
Filed Nov 4, 2026

Purchases and sales by month

$877K$877KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 4, 2026Houte Hans vanCFOSale plan3,300$15.38$50.8KForm 4
Nov 4, 2026Houte Hans vanCFOSale plan1,469$16.20$23.8KForm 4
Nov 3, 2026Christine RingChief Legal OfficerSale plan6,113$25.83$158KForm 4
Nov 2, 2026Christine RingChief Legal OfficerSale plan9,527$25.74$245KForm 4
Nov 2, 2026Christine RingChief Legal OfficerSale plan1,075$26.76$28.8KForm 4
Nov 2, 2026Gwenn HansenChief Scientific OfficerSale plan1,452$26.80$38.9KForm 4
Oct 30, 2026Gwenn HansenChief Scientific OfficerSale plan3,957$26.28$104KForm 4
Oct 30, 2026Houte Hans vanCFOSale2,834$26.28$74.5KForm 4
Oct 15, 2026Gwenn HansenChief Scientific OfficerSale plan1,452$25.00$36.3KForm 4
Oct 14, 2026Julia P GregoryDirectorSale22,583$23.40$529KForm 4
Oct 2, 2026Christine RingChief Legal OfficerSale plan5,786$23.19$134KForm 4
Sep 2, 2026Christine RingChief Legal OfficerSale plan400$26.64$10.7KForm 4
Sep 2, 2026Christine RingChief Legal OfficerSale plan5,387$25.69$138KForm 4
Sep 1, 2026Gwenn HansenChief Scientific OfficerSale plan1,452$25.47$37KForm 4
Aug 5, 2026Gwenn HansenChief Scientific OfficerSale plan4,356$25.00$109KForm 4
Aug 4, 2026Gwenn HansenChief Scientific OfficerSale plan2,611$24.64$64.3KForm 4
Aug 4, 2026Gwenn HansenChief Scientific OfficerSale plan1,500$23.87$35.8KForm 4
Aug 4, 2026Houte Hans vanCFOSale plan1,794$23.89$42.9KForm 4
Aug 4, 2026Houte Hans vanCFOSale plan2,967$24.65$73.1KForm 4
Aug 3, 2026Christine RingChief Legal OfficerSale plan16,589$23.05$382KForm 4
Jul 30, 2026Houte Hans vanCFOSale2,845$23.38$66.5KForm 4
Jul 30, 2026Christine RingChief Legal OfficerSale3,847$23.38$89.9KForm 4
Jul 2, 2026Christine RingChief Legal OfficerSale plan11,008$23.56$259KForm 4
Jun 25, 2026Gwenn HansenChief Scientific OfficerSale plan5,394$20.00$108KForm 4
Jun 25, 2026Christine RingChief Legal OfficerSale plan28,935$20.06$580KForm 4
Jun 2, 2026Christine RingChief Legal OfficerSale plan8,148$16.60$135KForm 4
May 5, 2026Houte Hans vanCFOSale plan582$17.18$10KForm 4
May 5, 2026Houte Hans vanCFOSale plan13,473$16.58$223KForm 4
May 4, 2026Christine RingChief Legal OfficerSale plan8,148$16.96$138KForm 4
May 1, 2026Christine RingChief Legal OfficerSale plan5,394$16.76$90.4KForm 4
Apr 30, 2026Houte Hans vanCFOSale2,388$16.65$39.8KForm 4
Apr 30, 2026Christine RingChief Legal OfficerSale3,214$16.65$53.5KForm 4
Apr 2, 2026Christine RingChief Legal OfficerSale plan8,148$15.24$124KForm 4
Mar 2, 2026Christine RingChief Legal OfficerSale plan8,148$15.44$126KForm 4
Feb 9, 2026Christine RingChief Legal OfficerSale plan14,261$16.66$238KForm 4
Jan 30, 2026Houte Hans vanCFOSale73$17.37$1.3KForm 4
Jan 30, 2026Houte Hans vanCFOSale3,588$16.58$59.5KForm 4
Jan 30, 2026Christine RingChief Legal OfficerSale88$17.37$1.5KForm 4
Jan 30, 2026Christine RingChief Legal OfficerSale4,333$16.58$71.8KForm 4
Jan 30, 2026Gwenn HansenChief Scientific OfficerSale98$17.37$1.7KForm 4
Jan 30, 2026Gwenn HansenChief Scientific OfficerSale4,797$16.58$79.5KForm 4
Jan 20, 2026Christine RingChief Legal OfficerSale plan3,760$18.42$69.3KForm 4
Dec 18, 2025Christine RingChief Legal OfficerSale plan3,560$17.87$63.6KForm 4
Dec 18, 2025Christine RingChief Legal OfficerSale plan200$18.56$3.7KForm 4
Nov 24, 2025Christine RingChief Legal OfficerSale plan37,600$17.07$642KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Christine RingChief Legal Officer–$3.8MNov 3, 2026
Houte Hans vanChief Financial Officer–$665KNov 4, 2026
Gwenn HansenChief Scientific Officer–$614KNov 2, 2026
Julia P GregoryDirector–$529KOct 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NRIX short interest

High short interest. 17.3% of NRIX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 2%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 18.94M NRIX shares were sold short, 17.3% of the shares outstanding, down 8.1% from the report before. At the average daily volume of 2.64M shares, buying them all back would take about 7.2 trading days (days to cover).

Shares short, % of all shares

17.3%May 15Oct 3019.8%

Days to cover

7.2May 15Oct 3024.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202618.94M17.33%-8%2.64M7.2
Oct 15, 202620.61M18.86%+17%2.24M9.2
Sep 30, 202617.66M16.16%-2%1.78M9.9
Sep 15, 202617.98M17.32%+0%1.28M14.1
Aug 31, 202617.95M17.30%-0%1.13M15.9
Aug 14, 202617.98M17.33%-2%993,10318.1
Jul 31, 202618.35M17.68%+2%1.02M18.0
Jul 15, 202617.98M17.32%+1%1.30M13.9
Jun 30, 202617.80M17.15%-11%3.28M5.4
Jun 15, 202620.02M19.37%+4%4.05M4.9
May 29, 202619.32M18.69%+4%1.30M14.9
May 15, 202618.63M18.02%-3%838,93122.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Nurix Therapeutics company events

Nurix Therapeutics filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.

  1. Nov 3, 2026AnnouncementNurix Therapeutics, Inc. announced that collaboration partner Sanofi S.A. had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program. Filing
  2. Oct 13, 2026ResultsReleased financial results. Filing
  3. Jul 9, 2026ResultsReleased financial results. Filing
  4. Jun 11, 2026AnnouncementThe Company announced updated data from the Phase 1 clinical trial of bexobrutideg (NX-5948). Filing
  5. Jun 8, 2026AgreementNurix Therapeutics, Inc. entered into a License and Collaboration Agreement, dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, “ Roche ”), pursuant to which Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its… Filing
  6. May 15, 2026VoteReported shareholder vote results. Filing
  7. Apr 8, 2026ResultsReleased financial results. Filing
  8. Mar 6, 2026AnnouncementAs previously disclosed, on August 4, 2021, Nurix Therapeutics, Inc., a Delaware corporation, entered into an equity distribution agreement with Piper Sandler & Co., which Equity Distribution Agreement was subsequently amended by Amendment No. 1 to the Equity Distribution Agreement on July 11, 2024… Filing
  9. Jan 28, 2026ResultsReleased financial results. Filing
  10. Jan 12, 2026AnnouncementShared information with investors. Filing
  11. Dec 9, 2025AnnouncementThe Company announced new clinical data from the Phase 1a/1b clinical trial of bexobrutideg (NX-5948) in patients with relapsed or refractory CLL and SLL, and on December 8, 2025, the Company announced new clinical data from patients with relapsed or refractory Waldenström macroglobulinemia (WM)… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Nurix Therapeutics financials

Famous investors that hold NRIX

5 of the 50 well-known investors we track reported holding NRIX in their latest 13F filing. The largest position is Cathie Wood's, worth $43.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 20261.85M$43.9M0.3%+3%
Israel Englander · Millennium ManagementQ3 2026412,768$9.8M0.0%+1874%
Ken Fisher · Fisher Asset ManagementQ3 2026356,843$8.5M0.0%-3%
Ken Griffin · Citadel AdvisorsQ3 2026164,201$3.9M0.0%-89%
Paul Tudor Jones · Tudor Investment CorpQ3 202651,588$1.2M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named NRIX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Deep Track Capital, LP13G/A5.5%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A4.4%
Nov 16, 2026Vestal Point Capital, LP13G/A6.4%
Nov 16, 2026Rubric Capital Management LP13G/A4.5%
Nov 16, 2026Deep Track Capital, LP13G/A5.5%
Nov 16, 2026Perceptive Advisors LLC13G/A4.9%
Nov 16, 2026Perceptive Advisors LLC13G/A4.9%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A4.4%
Nov 16, 2026Rubric Capital Management LP13G/A4.5%
Nov 16, 2026Vestal Point Capital, LP13G/A6.4%
Nov 5, 2026FMR LLC13G/A4.2%
Nov 5, 2026FMR LLC13G/A4.2%

Questions about Nurix Therapeutics, Inc. (NRIX) stock

Who owns the most NRIX stock?

The largest reported owner of Nurix Therapeutics, Inc. (NRIX) is BlackRock, Inc., with 8.5% of the company. In total, 212 funds and institutions reported holding NRIX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are NRIX insiders buying or selling?

In the last 12 months, NRIX insiders reported no open-market purchases and 45 sales worth $5.6M. The latest trade was on Nov 4, 2026. See every trade.

What is the short interest in NRIX?

As of Oct 30, 2026, 18.94M NRIX shares were sold short, 17.3% of the shares outstanding, down 8.1% from the report before. At the average daily volume of 2.64M shares, buying them all back would take about 7.2 trading days (days to cover). See the history.

Which famous investors hold NRIX?

5 of the 50 well-known investors we track reported NRIX in their latest 13F filing, including Cathie Wood, Israel Englander, Ken Fisher. The largest position is worth $43.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.